16th JBF Symposium
Advanced Search

Session Details

Symposium

[D1-A5]Advancing drug development: Comprehensive and optimum approaches to the immunogenicity assessment

Mon. Mar 3, 2025 5:35 PM - 7:05 PM JST
Mon. Mar 3, 2025 8:35 AM - 10:05 AM UTC
Medium Hall(2nd Floor)
Chairman:Hiroyuki Shimizu(Mitsubishi Tanabe Pharma Corporation), Hisanori Hara(B2S Life Sciences)
5:35 PM - 6:05 PM JST(8:35 AM - 9:05 AM UTC)

[D1-A5-01]Crafting a Science-Driven Immunogenicity Risk Assessment

*Joleen T White1 (1. Bill & Melinda Gates Medical Research Institute (Gates MRI))
6:05 PM - 6:35 PM JST(9:05 AM - 9:35 AM UTC)

[D1-A5-02]Telling the Whole Story: The Integrated Summary of Immunogenicity

*Paul D Chamberlain1 (1. Immunogenicity Integrated Platform)
6:35 PM - 7:05 PM JST(9:35 AM - 10:05 AM UTC)

[D1-A5-03]Update on Current Discussions in and Recommendations from the EBF on ADA Related Themes (1-Tier, Drug Tolerance, CoU for and beyond Biomarkers)

*Kyra J Cowan1 (1. European Bioanalysis Forum)
Back to Category List